Clinical Trials Sponsored by Regenerex, LLC

Total 11368 results

ReGenTree, LLC

Terminated

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

Neurotrophic Keratopathy

United States
ReGenTree, LLC

Completed

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 (ARISE-3)

Dry Eye | Dry Eye Syndromes

United States
ReGenTree, LLC

Completed

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

Dry Eye Syndrome

United States
ReGenTree, LLC

Recruiting

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

Neurotrophic Keratopathy

United States
ReGenTree, LLC

Completed

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

Dry Eye Syndrome

United States
Regenexx, LLC

Completed

Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears

Rotator Cuff Tear

United States
Regenexx, LLC

Terminated

A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment

Osteoarthritis, Knee

United States
Regenexx, LLC

Recruiting

Trial for Treating Painful Degenerative Disc Disease

Degenerative Disc Disease

United States
Regenexx, LLC

Recruiting

Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries

Craniocervical Injuries

United States
Regenexx, LLC

Terminated

Correlating the OA Knee Microenvironment to Outcomes After Regenexx-SD Treatment: A Multi-Site Study

Knee Osteoarthritis

United States
Regenexx, LLC

Enrolling by invitation

A Clinical Registry of Orthobiologics Procedures

Orthopedic Disorder

United States, Australia, India
Regenexx, LLC

Completed

Randomized Trial of Regenexx Stem Cell Support Formula

Knee Osteoarthritis

United States
Regenexx, LLC

Terminated

A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain

Low Back Pain

United States
Regenexx, LLC

Completed

Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment (KneeOA)

Osteoarthritis, Knee
Regenexx, LLC

Terminated

Nebulized PL for Post-COVID-19 Syndrome

Covid19

United States
Regenexx, LLC

Completed

Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage (PPP)

Knee Osteoarthritis

United States
Regenexx, LLC

Completed

Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to TKA

Knee Osteoarthritis

United States
Regenexx, LLC

Terminated

Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy

Radiculopathy | Herniated Disc | Disc Degeneration

United States
Regenexx, LLC

Completed

Regenexx™ SD Versus Exercise Therapy for ACL Tears

Anterior Cruciate Ligament Tear

United States
Regenexx, LLC

Withdrawn

Case Series on Using Bone Marrow Concentrate for Alar Ligament Injuries

Craniocervical Injuries

United States
ReGenTree, LLC
PPD

Terminated

A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds

Diabetes

United States
ReGenTree, LLC
ORA, Inc.

Completed

Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

Dry Eye | Dry Eye Syndrome
Talaris Therapeutics Inc.
Northwestern University; Duke University; Regenerex, LLC

Terminated

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

Kidney Failure

United States
Southeast Clinical Research Associates, LLC
Regeneron Pharmaceuticals

Withdrawn

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

Diabetic Macular Edema

United States
RegeneRx Biopharmaceuticals, Inc.

Terminated

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Epidermolysis Bullosa
NuGenerex Immuno-Oncology
Merck Sharp & Dohme LLC; NSABP Foundation Inc

Active, not recruiting

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

Triple-negative Breast Cancer

United States
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

ST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
RegeneRx Biopharmaceuticals, Inc.

Completed

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Pressure Ulcers

United States
Regeneron Pharmaceuticals

Not yet recruiting

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals

Recruiting

Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Food Allergy

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Korea, Republic of, Australia, France, Spain, Malaysia, Taiwan, Italy, Poland, United States, Thailand, United Kingdom, Belgium, Turkey, Czechia
Regeneron Pharmaceuticals

Recruiting

A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations (ENSEMBLE)

Congenital Hearing Loss Secondary to Biallelic Mutations in the Otoferlin Gene (OTOF) | Biallelic Mutations in the Gap Junction Beta 2 (GJB2) Gene | Digenic Mutations in GJB2/Gap Junction Beta 6 (GJB6) Genes

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1)

B-cell Non-Hodgkins Lymphoma (B-NHL)

United States, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Non-Alcoholic Steatohepatitis (NASH) in Adult Participants at Increased Genetic Risk for This Condition (NASHGEN-2)

Non-alcoholic Steatohepatitis (NASH) | Metabolic Dysfunction Associated Steatohepatitis (MASH)

United States, Korea, Republic of, Puerto Rico, Japan
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Recruiting

An Observational Study to Assess the Effectiveness and Safety of Cemiplimab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe (CEMI-LUNG) (CEMI-LUNG)

Non-small Cell Lung Cancer

Germany, Austria, France
Regeneron Pharmaceuticals

Recruiting

Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

United States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
Regeneron Pharmaceuticals

Recruiting

A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

Paroxysmal Nocturnal Hemoglobinuria

Mexico, Korea, Republic of, Turkey, Italy, United Kingdom, Thailand, Poland, Singapore, Spain, Taiwan, Canada, Japan, United States, Malaysia, Greece, Romania, Hungary
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (COMBINE-EGFR-1)

Advanced Solid Tumors

United States, Turkey
Regeneron Pharmaceuticals

Recruiting

T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Celiac Disease

United States
Regeneris Medical

Not yet recruiting

Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

Covid-19 Pneumonia | Cyotokine Storm
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Clear Cell Renal Cell Carcinoma (ccRCC)

United States
Regeneron Pharmaceuticals

Recruiting

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Advanced Malignancies

Japan
Regeneron Pharmaceuticals

Active, not recruiting

A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals

Active, not recruiting

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Diabetic Macular Edema (DME) | Neovascular Age-Related Macular Degeneration (nAMD)

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Venous Thromboembolism

Poland, Latvia, Canada, Belgium, Bulgaria, Hungary, Lithuania
Regeneron Pharmaceuticals

Suspended

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Oropharynx Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Australia
Regeneron Pharmaceuticals

Active, not recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Advanced Non-small Cell Lung Cancer

United States

3

Subscribe